Evidence map›Paper›PMID 31386218›Full record

ArticleStatistics in medicine2019

Dynamic prediction of Alzheimer's disease progression using features of multiple longitudinal outcomes and time-to-event data.

Kan Li, Sheng Luo

Abstract read
In one paragraph

Article in Statistics in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kan LiMerck Research Lab, Merck & Co, North Wales, Pennsylvania.ORCID 0000-0002-5762-7440
Sheng LuoDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0003-4214-5809

Funding

Statistical Methods for Clinical Trials with Multivariate Longitudinal OutcomesR01NS091307 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LUO, SHENG · 2015 to 2018
$1.2M
Shared genetic, epigenetic, and transcriptomic profiles between AD and PTSD: molecular insights into the heterogeneity of neuropsychiatric symptoms in Alzheimers DiseaseR56AG062302 · NIA · DUKE UNIVERSITY · PI CHIBA-FALEK, ORNIT, LUO, SHENG · 2018 to 2018
$788k
National Institute of Aging R56AG062302NIA NIH HHS R56 AG062302NINDS NIH HHS R01 NS091307
6 · The paper itself

Abstract

This paper is motivated by combining serial neurocognitive assessments and other clinical variables for monitoring the progression of Alzheimer's disease (AD). We propose a novel framework for the use of multiple longitudinal neurocognitive markers to predict the progression of AD. The conventional joint modeling longitudinal and survival data approach is not applicable when there is a large number of longitudinal outcomes. We introduce various approaches based on functional principal component for dimension reduction and feature extraction from multiple longitudinal outcomes. We use these features to extrapolate the health outcome trajectories and use scores on these features as predictors in a Cox proportional hazards model to conduct predictions over time. We propose a personalized dynamic prediction framework that can be updated as new observations collected to reflect the patient's latest prognosis, and thus intervention could be initiated in a timely manner. Simulation studies and application to the Alzheimer's Disease Neuroimaging Initiative dataset demonstrate the robustness of the method for the prediction of future health outcomes and risks of target events under various scenarios.

Indexed as

NeuroimagingProportional Hazards ModelsAlzheimer DiseaseBiomarkersDisease ProgressionHumansLongitudinal StudiesPredictive Value of TestsPrognosisSurvival AnalysisBiomarkersAUCfunctional data analysismultivariate longitudinal dataneuroimagingtwo stage

Identifiers

PMID31386218
PMCPMC6800781

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.